Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,331 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06205732 | A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. | unknown | — | 100 | Qianfoshan HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05021250 | SBRT With DIBH for HCC After TACE and Lipiodol Marking | unknown | N/A | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05185531 | A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma(Notable-HCC) | unknown | Phase 1 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06178809 | Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | unknown | — | 475 | Singlera Genomics Inc.INDUSTRY | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06144385 | A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06182865 | A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy | unknown | N/A | 10 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04422249 | A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy | unknown | N/A | 95 | Southwest Hospital, ChinaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06181318 | Quantitative MRI and Outcomes of Liver Resection | unknown | — | 33 | University Hospital HeidelbergOTHER | 0 | Dec 26, 2023 | clinicaltrials |
| NCT06178926 | Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation | unknown | N/A | 80 | Zhejiang Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05031949 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma(CCGLC-003) | unknown | Phase 1 | 20 | Zhang Bi Xiang, MDOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05103007 | PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer(CCGLC-004) | unknown | N/A | 200 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05520801 | Primary Hepatobiliary Cancer Cohort of Central China(CCGLC-002) | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05533892 | Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC(CCGLC-007) | unknown | Phase 1 | 30 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | unknown | N/A | 188 | Zhongda HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03839706 | Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation(PETMRIinHCC) | unknown | N/A | 20 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05429190 | Validation of SMS Protocol for HCC Screening in High-risk Patients | unknown | — | 470 | Erasmus Medical CenterOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06146127 | Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma(PREMED-CHC) | unknown | — | 300 | Inserm U955OTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05872828 | Cross-sectional Study of Chinese Liver Cancer Patients | unknown | — | 120 | The Nethersole School of NursingOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134973 | A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. | unknown | — | 1,000 | Tianjin Third Central HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06101758 | Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study(SARCOLIVER) | unknown | N/A | 125 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06088459 | NWRD06 DNA Plasmid for HCC After Radical Resection | unknown | Phase 1 | 9 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070623 | Follow up After TACE by Elastography and Color Doppler. | unknown | — | 54 | Assiut UniversityOTHER | 0 | Oct 6, 2023 | clinicaltrials |
| NCT06042842 | The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC | unknown | — | 102 | Assiut UniversityOTHER | 0 | Oct 4, 2023 | clinicaltrials |
| NCT06062706 | Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy | unknown | — | 3,448 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT06059885 | Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC | unknown | Phase 2 | 60 | Beijing 302 HospitalOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05352646 | NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 1 | 26 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05926336 | The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action | unknown | Phase 4 | 1,316 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05010434 | Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06006338 | 3D Printed Models for Liver Surgery | unknown | Phase 1 | 5 | Zhejiang Cancer HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039280 | Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization. | unknown | N/A | 150 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05992584 | Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06001567 | Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03447951 | A Study of PTS100 in Primary HCC Patients(OASES) | unknown | Phase 2 | 33 | Gongwin Biopharm Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05371873 | A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer | unknown | — | 250 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05443217 | Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments | unknown | — | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05443230 | Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment | unknown | — | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05448222 | Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies | unknown | — | 300 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06034977 | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2024source: clinicaltrials